Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study

Abstract EN

Objective.

Antinuclear antibodies (ANA) serve as screening tests for connective tissue diseases but have low specificity.

In this pilot study, we aimed to identify patients with first-time positive ANA and musculoskeletal complaints and correlate serum soluble vascular adhesion molecules as biomarkers.

Methods.

Prospective, observational study with 100 ANA-positive patients, comparing them to age- and gender-matched healthy controls (HC, n=75), was conducted.

Serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), endothelial-leukocyte adhesion molecule-1 (sELAM-1), and vascular cell adhesion molecule-1 (sVCAM-1) were measured.

A subgroup of patients with systemic sclerosis (SSc) treated with immunosuppressants was followed over 10 months.

Results.

Patients belonged to three main entities: rheumatoid arthritis (RA, n=32), collagen diseases (CD, n=56) also including systemic sclerosis (SSc, n=11), and other autoimmune diseases (n=12).

sICAM-1 was similar among groups.

sELAM-1 was elevated by 1.9-fold in only in SSc.

sVCAM-1 was elevated by 3.1-fold in RA and by 3.3-fold in CD and in other autoimmune diseases by 3.4-fold.

Seven SSc patients with immunosuppression had a 2.7-fold increased sVCAM-1 at baseline and reached the levels of healthy controls after 5 months, while CRP, ESR, and clinical parameters remained unchanged.

Conclusion.

Our study suggests that sVCAM-1 is a disease marker independent of standard serum parameters in several rheumatic diseases.

This study is registered with EU PAS Register number: EUPAS22154.